Iomeron (Iomeprol)

Iomeprol contains iodine atoms that strongly attenuate X‑ray photons. When administered intravenously, intra‑arterially, or intrathecally, the iodine increases the radiodensity of the blood pool and extracellular fluid, creating a contrast between vascular or cerebrospinal structures and surrounding tissues. This enhanced attenuation allows radiologists to delineate anatomical details more clearly during imaging examinations.

The specific dose of Iomeron is determined by the prescribing physician based on the type of imaging study, patient weight, renal function, and the required level of contrast enhancement. Dosing is individualized, and the prescriber follows established guidelines and product labeling to calculate the appropriate volume for each procedure.

Safety data for iomeprol in pregnant or lactating women are limited, and the product is generally classified as use only if clearly needed. The potential risks to the fetus or infant must be weighed against the diagnostic benefit. Healthcare providers should discuss possible alternatives and consider postponing elective imaging that requires contrast during pregnancy or breastfeeding.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity of Iomeron. GNH India works with hospitals, pharmacies, and procurement teams worldwide, and will request verification of trade or institutional credentials. After confirmation, the sales team provides pricing, availability, shipping details—including any cold‑chain requirements—and assists with import documentation.

Iomeron (iomeprol) is a low‑osmolality, non‑ionic iodinated contrast medium, offering a favorable safety profile compared with high‑osmolality agents that are associated with higher rates of discomfort and adverse reactions. Compared with other low‑osmolality agents, iomeprol provides comparable image quality and is often selected for its balance of viscosity, iodine concentration, and tolerability in a wide range of imaging studies.

Iomeron should be stored at controlled room temperature, typically below 25 °C, in its original sealed container. The solution must be protected from light, moisture, and freezing. Before use, inspect the vial for particulate matter or discoloration, and allow the product to reach ambient temperature if it has been stored in a cooler environment.

Iomeron is supplied as a sterile aqueous solution for injection and is administered by a qualified healthcare professional via intravenous, intra‑arterial, or intrathecal routes, depending on the imaging procedure. The injection is usually performed using a power injector or manual bolus, following aseptic technique and the dosage recommended by the prescribing physician.

The most serious adverse reactions to Iomeron include severe hypersensitivity reactions such as anaphylaxis, acute kidney injury especially in patients with pre‑existing renal impairment, and significant hemodynamic changes like profound hypotension or cardiac arrhythmias. Prompt recognition and emergency management are essential, and patients at risk should be closely monitored during and after administration.

Iomeron is contraindicated in patients with a known hypersensitivity to iomeprol or any component of the formulation, as well as in individuals with a history of severe allergic reactions to iodinated contrast media. Caution is also advised for patients with impaired renal function, uncontrolled thyroid disease, or severe cardiac conditions, and the decision to use the agent should be made by the treating physician after risk assessment.